Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/17/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
139 |
| 08/14/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
41 |
| 08/14/20 | 8-K | Current report filing |
|
8 | |
| 08/04/20 | 8-K | Current report filing |
|
44 | |
| 07/16/20 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
34 | |
| 07/15/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 07/13/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 07/13/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 07/13/20 | S-3/A | Registration statement for specified transactions by certain issuers |
|
44 | |
| 07/10/20 | UPLOAD | SEC-generated letter |
|
2 |
